xCures to Implement an Intermediate Size Expanded Access Protocol for ONC201 in H3 K27M-mutant Gliomas

LOS ALTOS, Calif.March 12, 2019 /PRNewswire/ — xCures and Cancer Commons are pleased to announce a collaboration with Oncoceutics to implement an Expanded Access program for ONC201. Part of this Expanded Access program is an intermediate size Expanded Access protocol for ONC201 in patients with H3 K27M-mutant glioma entitled “ONC018: Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline High Grade Gliomas” that was recently accepted by the U.S. Food and Drug Administration (FDA).

The H3 K27M mutation has been identified as an important prognostic indicator in aggressive midline gliomas that involve specific parts of the brain, including the thalamus, pons, or spinal cord. In 2016, the World Health Organization categorized any midline brain tumor that contains the H3 K27M mutation as the highest grade (IV) because the mutation confers such a poor prognosis. Beyond palliative radiation, no medical therapy has been shown to provide clinical benefit for patients with this mutation in their tumor. Pediatric patients are particularly impacted by this mutation, especially those with DIPG where 70-80% of the patients have the mutation. Continue reading…


Cancer Commons and xCures Invite Participation from Patients Who Try New Combo Therapy for Pancreatic Cancer

Treatment for metastatic pancreatic cancer has seen progress in recent years, but outcomes remain poor and treatment advances that can prolong patients’ lives, even for a few months, are eagerly awaited. Two papers published today in the scientific journal Nature Medicine report that a new combination of two drugs that are FDA-approved for other conditions may significantly delay progression of pancreatic cancer in cells and in mice. Furthermore, the first patient treated with this combination experienced a prolonged response that lasted almost 6 months.

In light of these promising results, Cancer Commons is partnering with xCures to track the experiences of patients who choose to try this new combination therapy. Continue reading…


Cancer Commons Founder to Speak at Molecular Med Tri-Con

Cancer Commons founder Marty Tenenbaum, PhD, will speak at the 26th International Molecular Medicine Tri-Conference in San Francisco on March 12. At 8:15 am, he will moderate an expert panel discussion on “Data Science Enabling Personalized Medicine“:

“Big data and machine learning have the potential to improve health, detecting disease at an earlier stage and personalizing interventions. The key ingredient, some say, is applying algorithms to population-wide datasets. But the question remains: is it enough to train smarter algorithms with broader datasets? What other approaches, diagnostics tools, and technologies do we need to accurately assess a patient’s unique needs and build a personalized intervention? A panel of experts across diagnostics, informatics, and therapeutics from government, academia, integrated health centers, data science, and biopharma will lead a highly interactive exploration of these issues and predict what it will take to realize the role of data science enabling personalized medicine.”

Learn more about this event at https://www.triconference.com/.

Marty Tenenbaum to Speak at Bridging Clinical Research & Clinical Health Care Collaborative

Cancer Commons founder Marty Tenenbaum, PhD, will speak at the upcoming Bridging Clinical Research & Clinical Health Care Collaborative at the National Academy of Sciences in Washington, DC, on March 4 at 5:00 pm. Marty, who founded Cancer Commons after his own battle with melanoma, will facilitate an expert panel discussion on “Reinventing Clinical Research and Cancer Care.” That same day, he will also lead a lunchtime discussion on “Shifting the Clinical Trials Paradigm From Approving Drugs to Curing Patients.”

In preparation for the conference, Marty has written a piece for Bridging Clinical that outlines his take on the increasing demand for patients in clinical research. An excerpt: “Those familiar with the current drug development process express skepticism that the system can ever be changed — and for good reason; many have tried and failed. However, a confluence of trends, from patient activism to the explosion of new therapies to an unprecedented open regulatory environment, make a paradigm shift from drug-developer-centric to patient-centric trials both necessary and possible.” Click here to read the full article.

Learn more about this event at https://www.bridgingclinical.com/.


Promising Developments for Brain Tumor Drug ONC201

In September, we announced our collaboration with Musella FoundationxCures, and Oncoceutics to help patients access ONC201, a potential new treatment for a type of brain tumor known as diffuse intrinsic pontine glioma (DIPG), as well as other gliomas with a genetic mutation known as H3 K27M.

Since then, several news stories have reported promising developments for ONC201. Check out the coverage:

  • The Philadelphia Inquirer: “Cancer therapy shows promise for some brain tumors”
  • Atrium Health: “Finding hope in the face of brain cancer: After being diagnosed with a brain tumor, Amanda’s future was uncertain. But participating in a Phase 2 clinical trial has given her more time, more hope and a new mission.” (Also covered on WSOC-TV)
  • Michigan Medicine: “Brain cancer patient finds hope with emerging new therapy”
  • Omaha World-Herald: “Experimental drug ‘nothing short of miraculous’ for father of 4 with super-rare brain tumor”

To learn more about our ONC201 project, click here.


Compassion Drives Emma Shtivelman’s Work with Cancer Patients


Emma Shtivelman, PhD

Chief scientist Emma Shtivelman’s expert, science-based opinion made such logical sense, and it also felt right in my soul. Ellen McGregor Kortan

I always say that Emma was an angel that appeared in my life. Rapidly, I saw that her advice was professional and that her insights matched the latest publications, so I have developed very strong trust in her… Moreover, what I appreciate the most about Emma is her human goodness and empathy. I have never felt I was just a case for her. She is really dedicated to the patient. — Marilou Gougeon

Emma is really up and up on the latest and newest available treatments… On top of that, you can tell that she truly cares…There is no money in the world that can buy that sort of support. It is the ultimate second opinion. — Phil Kauffman

To many of the patients whom she personally helps to make treatment decisions in the fight of their lives, chief scientist Emma Shtivelman, PhD, represents the heart, soul, and brain of Cancer Commons. Continue reading…


Cancer Commons Leadership to Speak at Precision Medicine World Conference—Patients Welcome!

Cancer Commons leadership, including founder Marty Tenenbaum, executive director Erika Vial Monteverdi, and editor in chief George Lundberg, are speaking at the 2019 Precision Medicine World Conference (PMWC) in Silicon Valley. Every year, the conference attracts doctors, innovators, and patients “to learn first-hand about the latest developments and advancements in precision medicine and cutting-edge new strategies and solutions that are changing how patients are treated.”

On January 22 at 8:45 am, Marty will lead a panel discussing the potential of real-world evidence to inform research and clinical decision making: “Traditionally, the majority of evidence regarding the benefits and risks of cancer treatments is derived from clinical trial populations. However, the vast majority of cancer patients receive treatment outside the context of clinical trials. There is tremendous motivation to evaluate the benefits and risks of cancer treatments delivered in the context of ‘real world’ care. Real-world evidence (RWE) is typically defined as treatment that is not delivered in accordance with an investigational protocol and therefore lacks clearly specified endpoints and assessment intervals for determining benefit. This session will cover opportunities and challenges in using real-world evidence to inform clinical decision making in cancer. The session will review opportunities and challenges in defining real world endpoints and the development of methods and analytical tools capable of generating insights from RWE.” Continue reading…


Happy Holidays from Cancer Commons


Erika Vial Monteverdi

The holiday season is an excellent time to reflect on the successes of the past year while looking forward to opportunities in the rapidly approaching new year.

We want to express our deepest appreciation to the Cancer Commons community; everyone’s involvement and support have been integral to our progress and success this year.

Our mission of leveraging the world’s best cancer knowledge to help advanced cancer patients and their physicians make optimal treatment decisions is particularly relevant in today’s rapidly evolving oncology landscape. Almost every day, we hear about some new molecular pathway that may hold the potential to inspire a novel therapeutic strategy. Too often, no one knows the optimal way to use available therapies, as there are too few patients and too many combinations of therapies possible. Continue reading…


Marty Tenenbaum to Speak at NYC Oncology Investor Conference

Cancer Commons founder Marty Tenenbaum, PhD, will speak at the NYC Oncology Investor Conference on October 30. Marty, who founded Cancer Commons after his own battle with melanoma, will discuss the potential for artificial intelligence to help find better cancer treatments.

Read the synopsis of Marty’s presentation, “Can AI Cure Cancer?”:
No one knows the optimal way to treat any cancer with currently available therapies. When clinical advances are made, it can take years for you and your doctor to find out about them. Getting access to breakthrough therapies, in a clinical trial or through expanded access, is problematic. Developing a new drug from scratch can take a decade or more and cost upwards of a billion dollars. AI can help. I will outline a plan, with the potential to save many thousands of lives, and a strategy for funding it through philanthropy and impact investing.

The NYC Oncology Investor Conference brings together “leading life science and oncology venture capitalists, family offices, lawyers, pharma executives, startup public and private cancer companies, and cancer foundations for a discussion of trends, opportunities, and risks in oncology investing, corporate presentations by a select group of public and private oncology companies, and updates on cutting edge science.”

Marty’s talk takes place on October 30 at 1:30pm Eastern time. Learn more about the NYC Oncology Investor Conference.